会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 11. 发明授权
    • Tracking system for an optical recording/reproducing apparatus having a
plurality of light spots
    • 具有多个光点的光记录/重放装置的跟踪系统
    • US5161243A
    • 1992-11-03
    • US3801
    • 1987-01-16
    • Takashi IshidaShunji O'HaraKenzo IshibashiToshio Satoh
    • Takashi IshidaShunji O'HaraKenzo IshibashiToshio Satoh
    • G11B7/09
    • G11B7/0946
    • In an optical recording and reproducing apparatus which forms at least first and second light spots on a track of an optical recording medium to record, reproduce or erase information, a movable range of the second light spot is limited to less than one half of a track pitch, normal to the track, from the track to prevent tracks other than a target gtrack from being miserased, misrecorded or misreproduced. When a deviation of the second light spot from the target track exceeds a predetermined amount, light emission of the second light spot is stopped to prevent a track other than the target track from being miserased, misrecorded, or misreproduced. When the deviation of the second light spot from the target track exceeds the predetermined amount, the second light spot is returned to a neutral position to prevent a track other than the target track from being miserased, misrecorded, or misreproduced.
    • 在光学记录和再现装置中,其至少在光学记录介质的轨道上形成第一和第二光斑以记录,再现或擦除信息,第二光斑的可移动范围被限制在小于轨道的一半 从轨道正常的轨道,以防止除了目标区域之外的轨迹被遗漏,误记或错误地产生。 当第二光点与目标轨道的偏差超过预定量时,停止第二光点的发光,以防止除了目标轨道以外的轨迹被误导,误记或错误地产生。 当第二光点与目标轨迹的偏差超过预定量时,第二光点返回到中立位置,以防止目标轨迹以外的轨迹被误导,误记或错误地产生。
    • 14. 发明授权
    • Ascorbic acid derivative
    • 抗坏血酸衍生物
    • US5194445A
    • 1993-03-16
    • US700176
    • 1991-05-20
    • Toshio SatohYasunori NiiroHisao KakegawaHitoshi Matsumoto
    • Toshio SatohYasunori NiiroHisao KakegawaHitoshi Matsumoto
    • C07D307/62
    • C07D307/62
    • The preparation for preventing and curing organ dysfunctions, provided by the present invention, is a medicament having the activity to prevent and cure organ dysfunctions which active oxygen species and active organic radical species would cause, and unconventionally improved in stability in vivo by containing, as an active component, the ascorbic acid derivative of the formula, ##STR1## wherein R.sub.2 is a group selected from the class consisting of an alkylcarbonyl lower alkyl group of which the terminal alkyl group has 7 inclusive to 15 inclusive carbon atoms, an alkyl group having 9 inclusive to 17 inclusive alkyl groups and an alkoxycarbonyl lower alkyl group of which the terminal alkoxy group has 7 inclusive to 20 inclusive carbon atoms; and the ascorbic acid derivative of the above formula in which R.sub.2 is an alkylcarbonyl lower alkyl group of which the terminal alkyl group has 7 inclusive to 15 inclusive carbon atoms is novel and disclosed in the present specification together with the process for its preparation.
    • PCT No.PCT / JP90 / 01157 Sec。 371日期1991年5月20日 102(e)日期1991年5月20日PCT提交1990年9月11日PCT公布。 公开号WO90 / 03471 1991年3月21日。本发明提供的预防和治疗器官功能障碍的制剂是具有预防和治疗活性氧物质和活性有机自由基物质将引起的器官功能障碍的活性的药物,并且非常规地改善 通过含有作为活性组分的下式的抗坏血酸衍生物,其中R2是选自末端烷基的烷基羰基低级烷基(包括末端烷基)为7以上的基团 碳原子数为9〜20的烷基,末端烷氧基为碳原子数为7〜20的烷氧基羰基低级烷基, 和上述式的抗坏血酸衍生物,其中R2是末端烷基具有7个包括15个碳原子的烷基羰基低级烷基,在本说明书中与其制备方法一起是新的和公开的。